| abstract |
The present invention relates to binding molecules specific for CD73 and uses thereof. The present disclosure provides anti-CD73 binding molecules, such as antibodies, and antigen-binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions and methods of diagnosing and treating diseases associated with CD73 expression, such as cancer. Can be, for example, by direct therapy with the anti-CD73 binding molecules disclosed herein (eg, naked antibodies or antibody drug conjugates that bind CD73), by binding with other antigens to anticancer agents such as immune checkpoint inhibitors (eg, anti-CTLA -4 and anti-PD-1 monoclonal antibodies), and/or to treat such diseases by combination therapy wherein these anti-CD73 molecules are administered before, after, or concurrently with chemotherapy. |